Literature DB >> 2190193

Management of chemotherapy-induced nausea and vomiting.

P V Tortorice1, M B O'Connell.   

Abstract

Cancer chemotherapy is associated with numerous toxicities such as nausea and vomiting (emesis). The frequency, onset, and duration of emesis depend largely on the emetogenic potential of specific agents. An exact mechanism for chemotherapy-induced emesis (CIE) is not known but is thought to occur through several noxious actions and numerous neuronal pathways. The three types of CIE are acute, delayed, and anticipatory. Nonchemotherapy causes of emesis should be considered before diagnosing CIE. Once the diagnosis is established, antiemetic regimens should be recommended based on characteristics of the patients and the agents. Phenothiazines, butyrophenones, cannabinoids, metoclopramide, corticosteroids, and benzodiazepines have been successful in preventing and treating CIE. Combinations of these drugs have also been successful and are still being investigated for improved emetic protection with fewer adverse reactions. Investigational agents such as serotonin antagonists may prove to be effective with few toxic effects. Despite the minimal information available on delayed and anticipatory nausea and vomiting, attempts should be made to treat them. Suggested guidelines for the management of CIE have been developed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2190193

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  9 in total

1.  Antiemetic study design: desirable objectives, stratifications and analyses.

Authors:  I N Olver
Journal:  Br J Cancer Suppl       Date:  1992-12

2.  Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists.

Authors:  Hideaki Ayuhara; Risa Takayanagi; Kiyoshi Okuyama; Koichi Yoshimoto; Takeshi Ozeki; Haruko Yokoyama; Yasuhiko Yamada
Journal:  Int J Clin Oncol       Date:  2009-12-05       Impact factor: 3.402

3.  A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.

Authors:  B Chevallier; P Cappelaere; T Splinter; M Fabbro; J L Wendling; L Cals; G Catimel; M Giovannini; D Khayat; P Bastit; N Claverie
Journal:  Support Care Cancer       Date:  1997-01       Impact factor: 3.603

Review 4.  Cannabinoids in clinical practice.

Authors:  E M Williamson; F J Evans
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 5.  Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.

Authors:  Anthony Markham; Eugene M Sorkin
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

6.  Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans.

Authors:  H Beaumont; J Jensen; A Carlsson; M Ruth; A Lehmann; Ge Boeckxstaens
Journal:  Br J Pharmacol       Date:  2008-12-06       Impact factor: 8.739

7.  Rotavirus stimulates release of serotonin (5-HT) from human enterochromaffin cells and activates brain structures involved in nausea and vomiting.

Authors:  Marie Hagbom; Claudia Istrate; David Engblom; Thommie Karlsson; Jesus Rodriguez-Diaz; Javier Buesa; John A Taylor; Vesa-Matti Loitto; Karl-Eric Magnusson; Håkan Ahlman; Ove Lundgren; Lennart Svensson
Journal:  PLoS Pathog       Date:  2011-07-14       Impact factor: 6.823

8.  Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort.

Authors:  Eric P Baron; Philippe Lucas; Joshua Eades; Olivia Hogue
Journal:  J Headache Pain       Date:  2018-05-24       Impact factor: 7.277

Review 9.  Antioxidants as precision weapons in war against cancer chemotherapy induced toxicity - Exploring the armoury of obscurity.

Authors:  Kanchanlata Singh; Mustansir Bhori; Yasar Arfat Kasu; Ganapathi Bhat; Thankamani Marar
Journal:  Saudi Pharm J       Date:  2017-12-19       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.